Current joint therapy usage in equine practice: Changes in the last 10 years

Osteoarthritis is a common clinical condition in the performance horse. In the last 10 years, there has been substantial growth in understanding of the disease and in the development of novel therapies.

To document changes in clinical use of joint therapies over the past 10 years. We also aimed to understand how newly developed therapies have been added to routine clinical practice.

Survey of veterinary professionals.

We administered an electronic survey to members of the American Association of the Equine Practitioners. Questions from a similar survey in 2009 were repeated and new questions were added. The responses were tabulated, analysed and compared to those of the previous survey.

A total of 407 completed surveys were returned. There were no significant differences between the current and previous surveys with respect to demographic parameters. Triamcinolone acetonide (TA) remained the most common corticosteroid used to treat high-motion joints. Methylprednisolone acetate (MPA) remained the most common corticosteroid to treat low-motion joints. The use of MPA for high-motion joints was significantly more common in 2009 than in 2019 (odds ratio [OR]: 2.38, 95% confidence interval [CI]: 1.66-3.42, P = .001). Biological therapies became more popular, and the likelihood of respondents reporting having used autologous conditioned serum was substantially higher in 2019 than in 2009 (OR: 4.24, 95% CI: 3.16-5.68, P < .001). Concomitant use of antibiotics with intra-articular medications became more common as well.

This is a report of survey data and not directly measured treatments.

There is a decrease in the use of MPA to treat high-motion joints. The use of biological therapies in joints has become more prevalent. There are clear differences in the use of joint therapies over time. While some differences agree with the scientific evidence, others are not fully concordant or are in direct conflict with the scientific literature.